Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial

• Published in: Complementary therapies in medicine 2022-06, Vol.66, p.102819-102819, Article 102819
• Main Authors: Mahjabeen, Wajiha, Khan, Dilshad Ahmed, Mirza, Shakil Ahmed
• Format: Article
• Language: English
• Subjects: Armed forces; Biomarkers - metabolism; Blood Glucose; C-reactive protein; Cellulose; Cholesterol; Clinical trials; Complications; Creatinine; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - metabolism; Dietary Supplements; Double-Blind Method; Glucose; Glucose - therapeutic use; Hemostasis; Hemostatics; Hepatitis; High density lipoprotein; Homeostasis; Humans; Hypoglycemic agents; Inflammation; Inflammation - drug therapy; Informed consent; Insulin; Insulin Resistance; Interleukin 6; Interleukins; Laboratories; Lipids; MicroRNAs; MicroRNAs - metabolism; MicroRNAs - pharmacology; MicroRNAs - therapeutic use; miRNA; Oxidation resistance; Oxidative Stress; Pathology; Placebos; Reduction; Resveratrol; Resveratrol - pharmacology; Resveratrol - therapeutic use; Ribonucleic acid; RNA; Side effects; Triglycerides; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Type-2 diabetes mellitus
• ISSN: 0965-2299; 1873-6963
• DOI: 10.1016/j.ctim.2022.102819

The objective was to determine the effects of resveratrol supplementation on glucose homeostasis, oxidative stress, inflammation and microRNAs expression in patients with diabetes mellitus type 2 on oral hypoglycemic drugs. This was a randomized, double blinded placebo-controlled parallel group trial. The diabetic patients (n = 110) were randomly assigned either to resveratrol (n = 55) and placebo (55) groups after informed consent and given once daily resveratrol 200 mg and cellulose capsules respectively for 24 weeks. Fasting glucose, insulin, HbA1c, lipid profile, TNF- α, IL-6, hs-CRP, MDA & circulatory microRNAs were measured at start and end of 24- week intervention. Out of 110 patients recruited, 94 patients completed the study comprising of 45 in resveratrol and 46 in placebo group. The resveratrol supplementation after 24 weeks was resulted in significant reduction [mean difference (95%CI)] of plasma glucose[− 0.50(−0.94 to −0.06)], insulin[− 1.31(−2.24 to −0.38)], homeostatic model assessment of insulin resistance[− 0.83(−1.37 to −0.29)], malondialdehyde[− 0.36(−0.61 to −0.11)], high sensitive-C-reactive protein[− 0.35(−0.70 to −0.01)], tumor necrosis factor-alpha[− 1.25(−1.90 to −0.61)] and interleukin-6[− 1.99(−3.29 to −0.69)]. More than two-fold down regulation in miRNA-34a, miRNA-375, miRNA-21, miRNA-192 and up regulation in miRNA-126 and miRNA-132 expression was noted in patients receiving resveratrol as compared to placebo. No side effects were reported during the trial. Resveratrol supplementation contributes in improvement of glycemic control by reducing insulin resistance. It has significant beneficial impact on chronic inflammation, oxidative stress and associated microRNA expression in diabetic patients. Thus, supplementation of resveratrol along with oral hypoglycemic agents may be useful in the reduction of diabetic associated complications. •Resveratrol along with recommended oral hypoglycemic agents is effective for prevention of disease progression in diabetes mellitus type 2.•Resveratrol significantly regulate glucose homeostasis through substantial decrease in HOMA-IR and insulin levels. Its effect in reduction of fasting glucose and HbA1c is significant but less potent.•Resveratrol proves to be an effective anti-inflammatory and anti-oxidative agent through significant decreases in levels of hs-CRP, IL-6, TNF-α and MDA.•Modulation of diabetes associated micro RNA expressions by resveratrol may represent a new treatment option in